BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 3:07:00 PM | Browse: 1962 | Download: 1801
 |
Received |
|
2013-02-21 09:47 |
 |
Peer-Review Started |
|
2013-02-21 20:18 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-04-18 15:32 |
 |
Revised |
|
2013-04-23 07:12 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-07-11 08:18 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-07-11 12:59 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-09-10 15:49 |
 |
Publish the Manuscript Online |
|
2013-11-17 20:09 |
| Category |
Obstetrics & Gynecology |
| Manuscript Type |
Autobiography |
| Article Title |
Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marco Lotti, Luisa Maria Busci, Luca Campanati, Fausto Catena, Federico Coccolini, Naoual Bakrin, Pierandrea De Iaco, Giorgio Ercolani, Giuseppe Grosso, Michele Pisano, Elia Poiasina, Diego Rossetti, Martina Rossi, Claudio Zamagni, Paolo Bertoli, Antonio Daniele Pinna, Luigi Frigerio and Luca Ansaloni |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Luca Ansaloni, MD, Unit of General Surgery 1, Papa Giovanni XXIII Hospital, Piazza OMS, Organizzazione mondiale della sanità 1, 24128 Bergamo, Italy. lansaloni@hpg23.it |
| Key Words |
Peritoneal carcinomatosis; Ovarian cancer; Cytoreductive surgery; Intraperitoneal chemotherapy; Hyperthermic intraperitoneal chemotherapy; Hyperthermia |
| Core Tip |
This is a report of a phase 2 prospective observational study, which served as a pilot study for the CHORINE trial protocol (http://www.chorine.org). Our pilot study supports the feasibility of neoadjuvant chemotherapy (NACT) followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for upfront treatment of advanced epithelial ovarian cancer. This combined therapy does not reduce the possibility to start the postoperative systemic chemotherapy in an acceptable period of time. We believe that in the upfront setting NACT can better select chemoresponsive patients, increasing their chance to take advantage from HIPEC, reducing the surgical stress and the perioperative complications. |
| Publish Date |
2013-11-17 20:09 |
| Citation |
Lotti M, Busci LM, Campanati L, Catena F, Coccolini F, Bakrin N, De Iaco P, Ercolani G, Grosso G, Pisano M, Poiasina E, Rossetti D, Rossi M, Zamagni C, Bertoli P, Pinna AD, Frigerio L, Ansaloni L. Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. World J Obstet Gynecol 2013; 2(4): 167-175
|
| URL |
http://www.wjgnet.com/2218-6220/full/v2/i4/167.htm |
| DOI |
http://dx.doi.org/10.5317/wjog.v2.i4.167 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.